Darbepoetin alfa biosimilar - Nichi-Iko Pharmaceutical/Aprogen

Drug Profile

Darbepoetin alfa biosimilar - Nichi-Iko Pharmaceutical/Aprogen

Alternative Names: AP 032

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aprogen; Nichi-Iko Pharmaceutical
  • Developer Nichi-Iko Pharmaceutical
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Anaemia

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for research development in Anaemia in Japan (SC, Injection)
  • 12 May 2015 Nichi-Iko plans a clinical trial for Anaemia in Japan (Nichi-Iko website, May 2015)
  • 12 May 2015 Early research in Anaemia in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top